# Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

> **NCT01839097** · PHASE1 · COMPLETED · sponsor: **Acrotech Biopharma Inc.** · enrollment: 23 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Belinostat
- **DRUG:** CHOP

## Key facts

- **NCT ID:** NCT01839097
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839097, "Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01839097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*